Physician profile
Rushia Butler
NPI 1376582072
$1,229.93
in general payments reported to CMS, 2019-2025
14 companies · $248 in 2025
The $248 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33.39 · 2023: $99.79 · 2024: $849 · 2025: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,196.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $401.02 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $157.54 | 2023-2024 | |
| Abbott Laboratories | $143.37 | 2024-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $102.49 | 2023-2024 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $94.02 | 2024 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $78.82 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $54.62 | 2024 | |
| Exact Sciences Corporation | $45.32 | 2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.99 | 2024 | Jardiance, Synjardy, Tradjenta |
| Novartis Pharmaceuticals Corporation | $33.96 | 2024 | |
| Pfizer INC. | $32.81 | 2019-2024 | |
| Paratek Pharmaceuticals, INC. | $22.06 | 2024 | Nuzyra |
| Sanofi Pasteur INC. | $15.51 | 2019 | |
| Esperion Therapeutics, INC. | $13.40 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rushia Butler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.